TISIDB

Summary
Symbol	KRT8
Name	keratin 8, type II
Aliases	CK8; CYK8; K2C8; KO; keratin 8; CK-8; cytokeratin 8; cytokeratin-8; type-II keratin Kb8; Keratin-8; Keratin, ......
Chromosomal Location	12q13.13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasm Nucleus, nucleoplasm Nucleus matrix
Domain	PF00038 Intermediate filament protein PF16208 Keratin type II head
Function	Together with KRT19, helps to link the contractile apparatus to dystrophin at the costameres of striated muscle.

> Gene Ontology [ TOP ]
Biological Process	GO:0001101 response to acid chemical GO:0001701 in utero embryonic development GO:0001890 placenta development GO:0001892 embryonic placenta development GO:0009415 response to water GO:0010035 response to inorganic substance GO:0010927 cellular component assembly involved in morphogenesis GO:0030239 myofibril assembly GO:0031032 actomyosin structure organization GO:0033209 tumor necrosis factor-mediated signaling pathway GO:0034612 response to tumor necrosis factor GO:0042692 muscle cell differentiation GO:0045214 sarcomere organization GO:0048568 embryonic organ development GO:0048608 reproductive structure development GO:0051146 striated muscle cell differentiation GO:0051599 response to hydrostatic pressure GO:0055001 muscle cell development GO:0055002 striated muscle cell development GO:0060706 cell differentiation involved in embryonic placenta development GO:0061458 reproductive system development GO:0071356 cellular response to tumor necrosis factor GO:0097191 extrinsic apoptotic signaling pathway GO:0097284 hepatocyte apoptotic process GO:1904019 epithelial cell apoptotic process
Molecular Function	GO:0097110 scaffold protein binding
Cellular Component	GO:0005882 intermediate filament GO:0016010 dystrophin-associated glycoprotein complex GO:0016363 nuclear matrix GO:0030016 myofibril GO:0030017 sarcomere GO:0030018 Z disc GO:0031674 I band GO:0034399 nuclear periphery GO:0042383 sarcolemma GO:0043034 costamere GO:0043292 contractile fiber GO:0044449 contractile fiber part GO:0045095 keratin filament GO:0045111 intermediate filament cytoskeleton GO:0090665 glycoprotein complex

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-1266738: Developmental Biology R-HSA-6805567: Keratinization

Summary
Symbol	KRT8
Name	keratin 8, type II
Aliases	CK8; CYK8; K2C8; KO; keratin 8; CK-8; cytokeratin 8; cytokeratin-8; type-II keratin Kb8; Keratin-8; Keratin, ......
Chromosomal Location	12q13.13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between KRT8 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	KRT8
Name	keratin 8, type II
Aliases	CK8; CYK8; K2C8; KO; keratin 8; CK-8; cytokeratin 8; cytokeratin-8; type-II keratin Kb8; Keratin-8; Keratin, ......
Chromosomal Location	12q13.13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of KRT8 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	KRT8
Name	keratin 8, type II
Aliases	CK8; CYK8; K2C8; KO; keratin 8; CK-8; cytokeratin 8; cytokeratin-8; type-II keratin Kb8; Keratin-8; Keratin, ......
Chromosomal Location	12q13.13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of KRT8 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.321	0.589
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.367	0.756
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.824	0.388
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.35	0.505
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.566	0.845
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.076	0.984
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.526	0.512
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	1.635	0.208
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.622	0.646
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.095	0.971
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.164	0.967
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.583	0.00258

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of KRT8 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	0	7.1	0.452
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	0	10	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	7.4	1.4	6	0.177
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	7.4	1.7	5.7	0.231
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	5.9	-1.1	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	0	12.5	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	9.1	-9.1	0.458
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	0	11.1	0.36
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	20	0	20	0.357
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	0	2.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	KRT8
Name	keratin 8, type II
Aliases	CK8; CYK8; K2C8; KO; keratin 8; CK-8; cytokeratin 8; cytokeratin-8; type-II keratin Kb8; Keratin-8; Keratin, ......
Chromosomal Location	12q13.13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of KRT8. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	KRT8
Name	keratin 8, type II
Aliases	CK8; CYK8; K2C8; KO; keratin 8; CK-8; cytokeratin 8; cytokeratin-8; type-II keratin Kb8; Keratin-8; Keratin, ......
Chromosomal Location	12q13.13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of KRT8. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by KRT8. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	KRT8
Name	keratin 8, type II
Aliases	CK8; CYK8; K2C8; KO; keratin 8; CK-8; cytokeratin 8; cytokeratin-8; type-II keratin Kb8; Keratin-8; Keratin, ......
Chromosomal Location	12q13.13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of KRT8. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	KRT8
Name	keratin 8, type II
Aliases	CK8; CYK8; K2C8; KO; keratin 8; CK-8; cytokeratin 8; cytokeratin-8; type-II keratin Kb8; Keratin-8; Keratin, ......
Chromosomal Location	12q13.13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of KRT8 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	KRT8
Name	keratin 8, type II
Aliases	CK8; CYK8; K2C8; KO; keratin 8; CK-8; cytokeratin 8; cytokeratin-8; type-II keratin Kb8; Keratin-8; Keratin, ......
Chromosomal Location	12q13.13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between KRT8 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	KRT8
Name	keratin 8, type II
Aliases	CK8; CYK8; K2C8; KO; keratin 8; CK-8; cytokeratin 8; cytokeratin-8; type-II keratin Kb8; Keratin-8; Keratin, ......
Chromosomal Location	12q13.13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting KRT8 collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting KRT8.

ID	Name	Drug Type	Targets	#Targets
DB00031	Tenecteplase	Biotech	ANXA2, CALR, CANX, CLEC3B, FGA, KRT8, LRP1, PLAUR, PLG, SERPINB2, ......	11
DB06245	Lanoteplase	Biotech	ANXA2, CALR, CANX, CLEC3B, F10, FGA, FN1, KLK1, KRT8, LAMA1, LAMA3 ......	17
DB09130	Copper	Small Molecule	A1BG, ACTG1, ACTN1, ACY1, AFM, AGT, AHCY, AHSG, AKR1A1, ANXA4, ANX ......	141

Browse KRT8